Mesothelin as a biomarker for targeted therapy.

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• CAR-T cell therapy is effective for B cell malignancies but limited for solid tumors due to target scarcity.
• Mesothelin (MSLN) is a tumor-associated antigen overexpressed in various solid tumors with limited normal tissue expression, making it an attractive therapeutic target.
• Existing strategies targeting MSLN include antibody-based drugs, vaccines, and CAR-T therapies, with ongoing clinical evaluations.

Purpose of the Study:

• To review the characteristics of mesothelin (MSLN) as a therapeutic target for solid tumors.
• To provide an overview of the development of MSLN-targeted immunotherapies, including CAR-T cell therapy.
• To discuss current challenges and propose strategies for enhancing MSLN-targeted immunotherapy efficacy.

Main Methods:

• Literature review of preclinical and clinical studies on mesothelin (MSLN) targeting strategies.
• Analysis of safety, efficacy, dosage, and pharmacokinetics data from clinical trials.
• Discussion of challenges and potential improvements in MSLN-targeted immunotherapy.

Main Results:

• Mesothelin (MSLN) is a viable target for solid tumor immunotherapy due to its broad overexpression on cancer cells and restricted expression in normal tissues.
• Various therapeutic strategies targeting MSLN, particularly CAR-T cell therapy, have demonstrated promise in preclinical and clinical settings.
• Clinical trials have provided data on the safety, efficacy, and pharmacokinetics of MSLN-targeted treatments.

Conclusions:

• Mesothelin (MSLN) represents a significant target for developing novel immunotherapies against solid tumors.
• CAR-T cell therapy targeting MSLN holds considerable promise, necessitating further research to optimize treatment outcomes.
• Addressing challenges and implementing innovative strategies are crucial for maximizing the effectiveness of MSLN-targeted immunotherapies.